Extract

BUILD 3 is a prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, event-driven, group sequential, phase III superiority study. The primary objective is to demonstrate that bosentan delays disease worsening or death in patients with Idiopathic Pulmonary Fibrosis.

Inclusion criteria

• Idiopathic pulmonary fibrosis

Country

• Australia
• Austria
• Belgium
• Canada
• Croatia
• Czech Republic
• France
• Germany
• Ireland
• Israel
• Italy
• Japan
• Korea, Republic of
• Netherlands
• Serbia
• Spain
• Switzerland
• United Kingdom
• United States

Links

• nct
• ictrp